We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Health and Fitness

Reset Paris

Status: Active

Jul 2nd 2019 - Aug 15th 2019

Reset Paris offers a wide range of high-end wellness services including spas, massage, sports and therapy classes. These services are delivered by highly qualified and experienced professionals with a holistic approach. Workshops based on matters like stress-relief, nutrition, focus, memory and sleep are also provided right at the office. The company has recruited a team of freelance professionals and tested their performance with B2B and B2C customers, developed a CRM platform and started collective classes with exceptional feedback. Reset is well-positioned to grow by selling health weeks to companies and increase its visibility through digital marketing.

read more read less
Log in to view amount pledged

    Log in to view target

    £1,173,000
    pre-money valuation

    7.86%
    equity available

    106
    investors

    £1,051
    pledge per investor

    11156777
    company number

    Dissolved
    company status

    18/01/2018
    incorporated 6 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    27 Mar 24 Crowdcube £111,430 / 111%
    News

0 comments

Log in to comment


Funding progress

Log in to view funding progress.


More from Health and Fitness

Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000

Log in to view amount pledged

    Log in to view target

    £1,173,000
    pre-money valuation

    7.86%
    equity available

    106
    investors

    £1,051
    pledge per investor

    11156777
    company number

    Dissolved
    company status

    18/01/2018
    incorporated 6 years

    Equity Calculator
    ?>
    Investment
    £
    Equity
    %
    Previous Funding rounds
    27 Mar 24 Crowdcube £111,430 / 111%
    News
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph